Risk factors for cardiovascular events in Japanese patients treated with fluvastatin from the long-term event monitoring (LEM) study

Current Vascular Pharmacology

Volumn 10, Issue 2, 2012, Pages 178-186

  Morishita, Ryuichi ^a   Itakura, Hiroshige ^b   Nakaya, Noriaki ^c   Yoshida, Masayuki ^d   Odawara, Masato ^e   Ichihara, Atsuhiro ^f   Mizuno, Kyoichi ^g  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b IBARAKI CHRISTIAN UNIVERSITY   (Japan)

^c Nakaya Clinic   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Clinical trial; Event; Fluvastatin; Hypercholesterolemia; Prevention

Indexed keywords

FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PROSPECTIVE STUDY; RISK FACTOR; SECONDARY PREVENTION; SMOKING;

AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COHORT STUDIES; DIABETES MELLITUS; DRUG MONITORING; FATTY ACIDS, MONOUNSATURATED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDOLES; JAPAN; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84857130781     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112799305049     Document Type: Article

References (34)

1. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation 2004; 110: 886-92.
2. Yusuf S, Lonn E, Bosch J. Lipid lowering for primary prevention. Lancet 2009; 373: 1152-5.
3. Forrester JS. Redefining normal low-density lipoprotein cholesterol: a strategy to unseat coronary disease as the nation's leading killer. J Am Coll Cardiol 2010; 56: 630-6.
4. Matsuzaki M, Kita T, Mabuchi H, et al.; J-LIT Study Group. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002; 66: 1087-95.
5. Nakamura H, Arakawa K, Itakura H, et al.; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 68: 1155-63.
6. Itakura H, Nakaya N, Kusunoki T, et al. Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: Efficacy and incidence of cardiac and other events in elderly patients (65 years old). J Cardiol 2011; 57: 77-88.
7. Japan Atherosclerosis Society (JAS). Guidelines for the treatment of Hyperlipidemia. J Jpn Atheroscler Soc 1997; 25: 1-34.
8. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52: 1769-81.
9. Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of doubleblind, randomized trials. Int J Cardiol 2007; 117: 64-74.
10. Jardine AG, Holdaas H, Fellström B, et al.; ALERT Study Investigators. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004; 4: 988-95.
11. Serruys PW, de Feyter P, Macaya C, et al.; Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287: 3215-22.
12. Lerakis S, El-Chami MF, Patel AD, et al. Effect of lipid levels and lipid-lowering therapy on restenosis after coronary artery stenting. Am J Med Sci 2006; 331: 270-3.
13. Lemos PA, de Feyter PJ, Serruys PW, et al. Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease. Int J Cardiol 2005; 98: 479-86.
14. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999; 144: 263-70.
15. Yasue H, Mizuno Y, Harada E, et al. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 2008; 51: 1742-8.
16. Matsuzawa Y, Kita T, Mabuchi H, et al.; J-LIT Study Group. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003; 67: 287-94.
17. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97: 1446-52.
18. Inami S, Okamatsu K, Takano M, et al. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia. Jpn Heart J 2004; 45: 969-75.
19. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprotein to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128: 11-8.
20. Yokoyama H, Kawasaki M, Ito Y, Minatoguchi S, Fujiwara H. Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity. J Am Coll Cardiol 2005; 46: 2031-7.
21. Corsini A, Pazzucconi F, Arnaboldi L, et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998; 31: 773-8.
22. Makabe S, Takahashi Y, Watanabe H, Murakami M, Ohba T, Ito H. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis 2010; 213: 377-84.
23. Schartl M, Bocksch W, Koschyk DH, et al.; for the German Atorvastatin Intravascular Ultrasound Study Investigators (GAIN). Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001; 104: 387-92.
24. Yamagishi T, Kato M, Koiwa Y, Omata K, Hasegawa H, Kanai H. Evaluation of plaque stabilization by fluvastatin with carotid in-tima-medial elasticity measured by a transcutaneous ultrasonic-based tissue characterization system. J Atheroscler Thromb 2009; 16: 662-73.
25. Morishita R. Statin biology beyond cholesterol lowering: hepatic statins vs. vascular statins. Immunol Endocr Metab Agents Med Chem 2008; 8: 103-4.
26. Abe K, Nakayama M, Yoshimura M, et al. Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relation with the -786T>C polymorphism. Pharmacogenet Genomics 2005; 15: 329-36.
27. Shimamura M, Sato N, Sata M, et al. Delayed postischemic treatment with fluvastatin improved cognitive impairment after stroke in rats. Stroke 2007; 38: 3251-8.
28. Kurinami H, Sato N, Shinohara M, et al. Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model. Int J Mol Med 2008; 21: 531-7.
29. Hanayama R, Shimizu H, Nakagami H, et al. Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action. Int J Mol Med 2009; 23: 581-8.
30. Komai N, Morishita R, Yamada S, et al. Mitogenic activity of oxidized lipoprotein (a) on human vascular smooth muscle cells. Hypertension 2002; 40: 310-4.
31. Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol 2011; 9: 62-86.
32. Ijioma N, Robinson JG. Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Rev Cardiovasc Ther 2011; 9: 131-45.
33. Kalhan A, Rees A. Statin/ezetimibe combination therapy: emerging evidence. Curr Opin Lipidol 2011; 22: 146-7.
34. Hatzitolios AI, Athyros VG, Karagiannis A, et al.; IMPROVE Collaborative Group. Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol 2009; 134: 322-9.